Xintela 관리

관리 기준 확인 2/4

Xintela's CEO는 Evy Lundgren-Åkerlund, Jan2009 에 임명되었습니다 의 임기는 15.42 년입니다. 총 연간 보상은 SEK 4.59M, 41% 로 구성됩니다. 41% 급여 및 59% 보너스(회사 주식 및 옵션 포함). 는 SEK 2.00M 가치에 해당하는 회사 주식의 1.23% 직접 소유합니다. 2.00M. 경영진과 이사회의 평균 재임 기간은 각각 11.4 년과 2.9 년입니다.

주요 정보

Evy Lundgren-Åkerlund

최고 경영자

SEK 4.6m

총 보상

CEO 급여 비율	41.0%
CEO 임기	15.8yrs
CEO 소유권	1.2%
경영진 평균 재임 기간	11.8yrs
이사회 평균 재임 기간	3.3yrs

최근 관리 업데이트

Recent updates

Calculating The Fair Value Of Xintela AB (publ) (STO:XINT)

Nov 04

CEO 보상 분석

Evy Lundgren-Åkerlund 의 보수는 Xintela 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-SEK 41m
Mar 31 2024	n/a	n/a	-SEK 49m
Dec 31 2023	SEK 5m	SEK 2m	-SEK 54m
Sep 30 2023	n/a	n/a	-SEK 59m
Jun 30 2023	n/a	n/a	-SEK 65m
Mar 31 2023	n/a	n/a	-SEK 66m
Dec 31 2022	SEK 4m	SEK 2m	-SEK 66m
Sep 30 2022	n/a	n/a	-SEK 67m
Jun 30 2022	n/a	n/a	-SEK 68m
Mar 31 2022	n/a	n/a	-SEK 64m
Dec 31 2021	SEK 3m	SEK 2m	-SEK 60m
Sep 30 2021	n/a	n/a	-SEK 68m
Jun 30 2021	n/a	n/a	-SEK 60m
Mar 31 2021	n/a	n/a	-SEK 54m
Dec 31 2020	SEK 3m	SEK 2m	-SEK 50m
Sep 30 2020	n/a	n/a	-SEK 40m
Jun 30 2020	n/a	n/a	-SEK 40m
Mar 31 2020	n/a	n/a	-SEK 42m
Dec 31 2019	SEK 3m	SEK 1m	-SEK 44m
Sep 30 2019	n/a	n/a	-SEK 37m
Jun 30 2019	n/a	n/a	-SEK 33m
Mar 31 2019	n/a	n/a	-SEK 28m
Dec 31 2018	SEK 3m	SEK 1m	-SEK 26m
Sep 30 2018	n/a	n/a	-SEK 24m
Jun 30 2018	n/a	n/a	-SEK 25m
Mar 31 2018	n/a	n/a	-SEK 24m
Dec 31 2017	SEK 3m	SEK 1m	-SEK 22m

보상 대 시장: Evy 의 총 보상 ($USD 439.71K )은 Swedish 시장( $USD 257.75K ).

보상과 수익: 회사가 수익성이 없는 동안 Evy 의 보상이 증가했습니다.

CEO

Evy Lundgren-Åkerlund (67 yo)

15.8yrs

테뉴어

SEK 4,589,000

보상

Dr. Evy Lundgren-Åkerlund, BSc, Ph D, Assoc Prof, serves as Chief Executive Officer at Xintela AB (publ) and has been its Executive Director since 2009. Dr. Lundgren-Åkerlund had been the Chief Executive O...

리더십 팀

이름	위치	테뉴어	보상	소유권
Gregory Batcheller	Executive Chairman of the Board	13.8yrs	SEK 383.00k	0.80% SEK 2.0m
Evy Lundgren-Åkerlund	Chief Executive Officer	15.8yrs	SEK 4.59m	1.23% SEK 3.1m
Gunnar Telhammar	CFO & Finance Director	11.8yrs	데이터 없음	0.073% SEK 183.6k
Lucienne Vonk	Chief Scientific Officer	less than a year	데이터 없음	데이터 없음
Per Goran Norlen	Chief Medical Officer	2yrs	데이터 없음	데이터 없음
Camilla Wennersten	Director of Clinical Development	no data	데이터 없음	0.0016% SEK 4.0k

11.8yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 관리: XINT 의 관리팀은 노련하고 경험 (평균 재직 기간 11.4 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Gregory Batcheller	Executive Chairman of the Board	13.8yrs	SEK 383.00k	0.80% SEK 2.0m
Thomas Eldered	Director	1.9yrs	SEK 17.00k	데이터 없음
Lars Hedbys	Independent Director	3.3yrs	SEK 197.00k	0.064% SEK 162.0k
Hans-Joachim Simons	Director	2.4yrs	SEK 99.00k	데이터 없음
Maarten de Chateau	Independent Director	3.8yrs	SEK 197.00k	0.43% SEK 1.1m

3.3yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: XINT 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Xintela 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Xintela Appoints Lucienne Vonk as Chief Scientific Officer

Less than half of directors are independent

Xintela AB (Publ) Appoints Peter Ekolind as Acting CEO, Effective October 1, 2022

Less than half of directors are independent

Chief Executive Officer recently bought kr116k worth of stock

CFO & Finance Director recently bought kr51k worth of stock

Recent updates

New major risk - Share price stability

New major risk - Negative shareholders equity

Xintela AB (publ) to Report Q1, 2024 Results on May 24, 2024

Xintela Appoints Lucienne Vonk as Chief Scientific Officer

Xintela Publishes Efficacy Results with EQSTEM from Preclinical Equine OA Study

New major risk - Shareholder dilution

Xintela's Stem Cell Product, Xstem, Assessed as Safe At All Dose Levels in Knee Osteoarthritis Clinical Study

Xintela Completes XSTEM Dosing at Third and Final Dose Level in Knee Osteoarthritis Clinical Study

Xintela AB (publ) Announces Clinical Study with XSTEM for Knee Oeoarthritis Makes Good Progress

Less than half of directors are independent

Xintela Starts Next Dose Level of Xstem in Knee Osteoarthritis Clinical Study

Calculating The Fair Value Of Xintela AB (publ) (STO:XINT)

Xintela Completes Dosing of Xstem First Dose Level in Knee Osteoarthritis Clinical Study

Xintela AB (Publ) Appoints Peter Ekolind as Acting CEO, Effective October 1, 2022

Xintela AB (publ) Starts Clinical Study with XSTEM for Difficult-To-Heal Leg Ulcers

Xintela Receives Approval for Clinical Study with XSTEM on Difficult-to-Heal Venous Leg Ulcers

Less than half of directors are independent

Xintela Starts Clinical Study of XSTEM® in Knee Osteoarthritis

Xintela AB (Publ) Receives Grant of 4.8 Million SEK from Vinnova

Xintela Signs Agreement with CRO for Phase I/II study

Chief Executive Officer recently bought kr116k worth of stock

CFO & Finance Director recently bought kr51k worth of stock

Xintela AB (Publ) Receives Permission from the Medical Products Agency to Produce Cell Therapy Products

Xintela to Develop Stem Cell Therapy for Difficult-To-Heal Wounds

Xintela AB (publ) Publishes Results from Glioblastoma Antibody Study

New 90-day low: kr2.96

Full year 2020 earnings released: kr0.68 loss per share (vs kr1.10 loss in FY 2019)

Xintela AB (publ) to Report Q1, 2021 Results on May 21, 2021

Xintela AB (publ) Receives Notice of Allowance from USPTO for the Treatment of Brain Tumors

Xintela Recruits Jeffrey Abbey to Targinta as Senior Management Advisor

Xintela AB (publ) to Report Fiscal Year 2020 Results on Feb 26, 2021

Xintela AB (Publ) Appoints Lars Hedbys to Its Board of Directors

New 90-day low: kr2.98

Xintela Announces Promising Results of Human Stem Cells XSTEM in Preclinical Acute Respiratory Distress Syndrome Study

New 90-day low: kr3.78

Xintela AB (publ) to Report Nine Months, 2020 Results on Nov 27, 2020

Xintela AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 36.70987 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령